PharmaLogic to Acquire Lantheus CDMO Business and New Jersey Facility
PharmaLogic says the acquisition will expand U.S. therapeutic manufacturing capacity and create a transatlantic CDMO platform focused on radioligand therapies.
Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapiesWALTHAM, Mass., Nov. 9, 2026 // -- PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract dev…